SLA: Preliminary Findings of BrainStorm’s Phase IIa Study Reported as “Extremely Optimistic”
BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Prof. Dimitrios Karussis, Principal Investigator of the Company’s clinical trials at Hadassah Medical Center in Jerusalem, presented some of his preliminary findings from…